✦ LIBER ✦

O.161 High SVR rates with 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 patients with a week-4 virological response

✍ Scribed by P. Ferenci; T. Scherzer; H. Laferl; K. Staufer; A. Maieron; M. Gschwantler; H. Brunner; R. Hubmann; C. Datz; M. Bischof; R. Stauber; H. Kessler; P. Steindl-Munda

Book ID: 117770194
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 140 KB
Volume: 36
Category: Article
ISSN: 1386-6532
DOI: 10.1016/s1386-6532(06)80153-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

8 24 Week treatment regimen with peginte

8 24 Week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 ‘super-responders’

✍ P. Ferenci; U. Bergholz; H. Laferl; T.M. Scherzer; A. Maieron; M. Gschwantler; H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 159 KB

P.238 High sustained virological respons

P.238 High sustained virological response (SVR) rates with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in haemodialysed CHC patients awaiting renal transplant

✍ M. Rendina; A. Schena; N.M. Castellaneta; F. Losito; A.C. Amoruso; G. Stallone; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 144 KB

[613] VIROLOGICAL RESPONSE AT 4 AND 12 W

[613] VIROLOGICAL RESPONSE AT 4 AND 12 WEEKS PREDICT HIGH RATES OF SUSTAINED VIROLOGICAL RESPONSE IN GENOTYPE 1 PATIENTS TREATED WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN

✍ P. Marcellin; S.J. Hadziyannis; T. Berg; J.M. Sanchez-Tapias; J.-P. Bronowicki; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 259 KB

734 Peginterferon alpha-2a (PEGASYS) plu

734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial

✍ M.L. Shiffman; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacons; J. Rase 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB

O.160 16 or 24 weeks of peginterferon al

O.160 16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE)

✍ S. Zeuzem; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacon; E. Godofsky; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 143 KB

328 Comparison of 48 or 72 weeks of trea

328 Comparison of 48 or 72 weeks of treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in treatment-naive patients with chronic hepatitis C infected with HCV genotype 1

✍ Thomas Berg; M. Von Wagner; H. Hinrichsen; T. Heintges; P. Buggisch; T. Goeser; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB